* ProQR Therapeutics NV PRQR.OQ reported a quarterly
adjusted
loss of 3 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -10 cents. The mean expectation of six analysts
for the quarter was for a loss of 12 cents per share. Wall
Street expected results to range from -17 cents to -8 cents per
share.
* Revenue rose 407.6% to $6.31 million from a year ago;
analysts
expected €11.46 million.
* ProQR Therapeutics NV's reported EPS for the quarter was a
loss
of 3 cents.
* The company reported a quarterly loss of €2.69 million.
* ProQR Therapeutics NV shares had risen by 10.2% this
quarter and
lost 7.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 9.5%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for ProQR
Therapeutics NV is $5.00
This summary was machine generated from LSEG data August 8 at
03:49 p.m. UTC. All figures in euros unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.12 -0.03 Beat
Mar. 31 2024 -0.11 -0.09 Beat
Dec. 31 2023 0.01 -0.07 Missed
Sep. 30 2023 -0.09 -0.07 Beat